Nader Al Nakouzi1, Sylvestre Le Moulec2, Laurence Albigès3, Chris Wang1, Philippe Beuzeboc4, Marine Gross-Goupil5, Thibault de La Motte Rouge6, Aline Guillot7, Dorota Gajda8, Christophe Massard9, Martin Gleave1, Karim Fizazi3, Yohann Loriot10. 1. Vancouver Prostate Centre, University of British Columbia, Vancouver, British Columbia, Canada. 2. Department of Medical Oncology, Val de Grâce Hospital, Paris, France. 3. Department of Cancer Medicine, Gustave Roussy, Cancer Campus, Grand Paris, University of Paris-Sud, and INSERM U981, Villejuif, France. 4. Department of Medical Oncology, Institut Curie, Paris, France. 5. Department of Medical Oncology, CHU de Bordeaux, Bordeaux, France. 6. Pitié-Salpetrière Hospital, Paris, France. 7. Institut de Cancérologie de la Loire, Saint-Etienne, France. 8. Biostatistics and Epidemiology unit, Institut Gustave Roussy, Cancer Campus, Grand Paris, Villejuif, France. 9. Department of Cancer Medicine, Gustave Roussy, Cancer Campus, Grand Paris, University of Paris-Sud, and INSERM U981, Villejuif, France. Electronic address: massard@igr.fr. 10. Department of Cancer Medicine, Gustave Roussy, Cancer Campus, Grand Paris, University of Paris-Sud, and INSERM U981, Villejuif, France. Electronic address: yohann.loriot@gustaveroussy.fr.
Abstract
BACKGROUND: Cabazitaxel, abiraterone acetate (AA), and enzalutamide have been approved for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) following docetaxel chemotherapy. Whether taxanes and next-generation androgen receptor (AR) axis inhibitors are cross-resistant or not is a subject of debate. OBJECTIVE: To evaluate the antitumour activity of cabazitaxel in mCRPC pretreated with abiraterone or enzalutamide. DESIGN, SETTING, AND PARTICIPANTS: The antitumour activity of cabazitaxel was assessed in patients with mCRPC and progressive disease after treatment with docetaxel and AA. In parallel, cabazitaxel antitumour activity was studied in enzalutamide-resistant models. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Changes in prostate-specific antigen (PSA) levels and progression-free survival were used to determine the activity of cabazitaxel treatment. Cell proliferation, immunofluorescence, and AR transactivation assay were used in enzalutamide-resistant models. RESULTS AND LIMITATIONS: A total of 79 patients who had progressive mCRPC after docetaxel (median: 8 cycles; range: 4-12 mo), and AA (median: 4.8 mo; range:1-55 mo) received cabazitaxel 25mg/m(2) every 3 weeks (median: 6 cycles; range:1-15 cycles). A PSA decline ≥30% was achieved in 48 patients (62%; 95% confidence interval [CI], 51-73), and a decline ≥50% was achieved in 28 patients (35%; 95% CI, 25-47). The median progression-free survival and overall survival were 4.4 and 10.9 mo, respectively. In vitro, cabazitaxel decreased cell viability in both enzalutamide-sensitive and enzalutamide-resistant prostate cancer cells within the same range of concentrations. PC3, an AR-negative cell line, exhibited similar sensitivity to cabazitaxel. CONCLUSIONS: Cabazitaxel and AR-pathway inhibitors are not cross-resistant. Preclinical data suggest that cabazitaxel activity does not act mainly through AR axis inhibition. PATIENT SUMMARY: The antitumour activity of cabazitaxel, a chemotherapy agent, was studied in prostate cancer resistant to conventional hormonal therapy and to more recent endocrine therapies (abiraterone or enzalutamide). Cabazitaxel retained anticancer activity in more than half of the cases.
BACKGROUND:Cabazitaxel, abiraterone acetate (AA), and enzalutamide have been approved for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) following docetaxel chemotherapy. Whether taxanes and next-generation androgen receptor (AR) axis inhibitors are cross-resistant or not is a subject of debate. OBJECTIVE: To evaluate the antitumour activity of cabazitaxel in mCRPC pretreated with abiraterone or enzalutamide. DESIGN, SETTING, AND PARTICIPANTS: The antitumour activity of cabazitaxel was assessed in patients with mCRPC and progressive disease after treatment with docetaxel and AA. In parallel, cabazitaxel antitumour activity was studied in enzalutamide-resistant models. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Changes in prostate-specific antigen (PSA) levels and progression-free survival were used to determine the activity of cabazitaxel treatment. Cell proliferation, immunofluorescence, and AR transactivation assay were used in enzalutamide-resistant models. RESULTS AND LIMITATIONS: A total of 79 patients who had progressive mCRPC after docetaxel (median: 8 cycles; range: 4-12 mo), and AA (median: 4.8 mo; range:1-55 mo) received cabazitaxel 25mg/m(2) every 3 weeks (median: 6 cycles; range:1-15 cycles). A PSA decline ≥30% was achieved in 48 patients (62%; 95% confidence interval [CI], 51-73), and a decline ≥50% was achieved in 28 patients (35%; 95% CI, 25-47). The median progression-free survival and overall survival were 4.4 and 10.9 mo, respectively. In vitro, cabazitaxel decreased cell viability in both enzalutamide-sensitive and enzalutamide-resistant prostate cancer cells within the same range of concentrations. PC3, an AR-negative cell line, exhibited similar sensitivity to cabazitaxel. CONCLUSIONS:Cabazitaxel and AR-pathway inhibitors are not cross-resistant. Preclinical data suggest that cabazitaxel activity does not act mainly through AR axis inhibition. PATIENT SUMMARY: The antitumour activity of cabazitaxel, a chemotherapy agent, was studied in prostate cancer resistant to conventional hormonal therapy and to more recent endocrine therapies (abiraterone or enzalutamide). Cabazitaxel retained anticancer activity in more than half of the cases.
Authors: Daniel W Yokom; John Stewart; Nimira S Alimohamed; Eric Winquist; Scott Berry; Stacey Hubay; Jean-Baptiste Lattouf; Helene Leonard; Carla Girolametto; Fred Saad; Srikala S Sridhar Journal: Can Urol Assoc J Date: 2018-04-06 Impact factor: 1.862
Authors: Alan P Lombard; Chengfei Liu; Cameron M Armstrong; Vito Cucchiara; Xinwei Gu; Wei Lou; Christopher P Evans; Allen C Gao Journal: Mol Cancer Ther Date: 2017-07-11 Impact factor: 6.261